Anti-counterfeit drug initiative for UK

4 June 2006

The Royal Pharmaceutical Society of Great Britain and the Medicines and Healthcare products Regulatory Authority (MHRA) have launched a joint-initiative to combat the threat of counterfeit drugs. Guidance is available for pharmacists from both the RPSGB and the MHRA's web sites. David Pruce, director of practice and quality at the RPSGB said: counterfeit medicines can be extremely dangerous. They contain little or no active medicine, a totally different medicine or a toxic chemical."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight